Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.7K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

652
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
652
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.4K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

338
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Leukemia·2026
Same author

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

Blood cancer journal·2025
Same author

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?

Clinical lymphoma, myeloma & leukemia·2025
Same author

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Leukemia·2025
Same author

Management of chronic myeloid leukemia in 2025.

Cancer·2025
Same author

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

Leukemia & lymphoma·2025

Related Experiment Video

Updated: Nov 29, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.1K

The New ELN Recommendations for Treating CML.

Rüdiger Hehlmann1

  • 1ELN-Foundation, Weinheim and Medical Faculty Mannheim of Heidelberg University, 69126 Mannheim, Germany.

Journal of Clinical Medicine
|November 19, 2020
PubMed
Summary
This summary is machine-generated.

Achieving deep molecular response in chronic myeloid leukemia (CML) allows for treatment discontinuation and improved quality of life. Faster responses with newer therapies do not improve survival and may increase toxicity, making generic imatinib a cost-effective first-line option.

Keywords:
ELN recommendationsblast crisischronic myeloid leukemiadiagnosismonitoringtreatmenttreatment-free remission

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

465
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

3.2K

Related Experiment Videos

Last Updated: Nov 29, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

465
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

3.2K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myeloid leukemia (CML) treatment has shifted from survival to quality of life, aiming for treatment-free remission (TFR).
  • Deep molecular response (DMR) is key for treatment discontinuation in CML management.
  • Tyrosine kinase inhibitors (TKIs) are standard first-line CML therapies.

Purpose of the Study:

  • To reevaluate the role of second-generation (2G)-TKIs in first-line CML therapy.
  • To assess the impact of faster response on survival and toxicity.
  • To identify optimal first-line CML treatment strategies considering cost-effectiveness and long-term outcomes.

Main Methods:

  • Analysis of long-term randomized trials comparing different TKIs and doses.
  • Evaluation of treatment-related toxicities, including cumulative and long-term side effects.
  • Consideration of patient comorbidities, contraindications, and risk stratification using the EUTOS score.

Main Results:

  • Faster responses achieved with higher imatinib doses or 2G-TKIs did not translate into improved survival.
  • Serious and frequent toxicities associated with 2G-TKIs necessitate reevaluation of their first-line use.
  • Generic imatinib emerges as the most cost-effective first-line therapy for chronic phase CML.

Conclusions:

  • Generic imatinib is recommended as the most cost-effective first-line therapy for chronic phase CML.
  • Treatment changes are advised for intolerance or failure to achieve molecular milestones.
  • Managing chronic low-grade side effects is crucial due to the likelihood of lifelong TKI exposure.